Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis?

Taştemur, Şeyma; Ataseven, Hilmi

doi:10.1016/j.mehy.2020.110018

Cited by 23 publications

(20 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our cohort, those who died had a significantly higher use of NSAIDs (10% vs. 3.84%, p=0.024) and statins (42.2% vs. 30.4%, p=0.035). Many studies have reported PPI [28,29] use as a risk factor, and although our data show a similar trend, it did not reach statistical significance.…”

Section: Discussioncontrasting

confidence: 97%

In-Hospital Mortality and Prediction in an Urban U.S. Population With COVID-19

Rustgi¹,

Makar²,

Minacapelli³

et al. 2020

Cureus

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) has touched every aspect of society, and as the pandemic continues around the globe, many of the clinical factors that influence the disease course remain unclear. A useful clinical decision-making tool is a risk stratification model to determine in-hospital mortality as defined in this study. The study was performed at Robert Wood Johnson University Hospital (RWJUH) in New Brunswick, New Jersey, USA. Data was extracted from our electronic medical records on 44 variables that included demographic, clinical, laboratory tests, treatments, and mortality information. We used the least absolute shrinkage and selection operator regression with corrected Akaike's information criterion to identify a subset of variables that yielded the smallest estimated prediction error for the risk of in-hospital mortality. During the study period, 808 COVID-19 patients were admitted to RWJUH. The sample size was limited to patients with at least one confirmed in-house positive nasopharyngeal swab COVID-19 test. Pregnant patients or those who were transferred to our facility were excluded. Patients who were in observation and were discharged from the emergency room were also excluded. A total of 403 patients had complete values for all variables and were eligible for the study. We identified significant clinical, laboratory, and radiologic variables determining severe outcomes and mortality. An in-hospital mortality risk calculator was created after the identification of significant factors for the specific cohort, which were abnormal CT scan or chest X-ray, chronic kidney disease, age, white blood cell count, platelet count, alanine aminotransferase, and aspartate transaminase with a sensitivity, specificity, and negative predictive value of 82%, 72%, and 93%, respectively. While numerous reports from around the globe have helped outline the pandemic, demographic factors vary widely. This study is more applicable to an urban, highly diverse population in the United States.

show abstract

Section: Discussioncontrasting

confidence: 97%

In-Hospital Mortality and Prediction in an Urban U.S. Population With COVID-19

Rustgi¹,

Makar²,

Minacapelli³

et al. 2020

Cureus

View full text Add to dashboard Cite

show abstract

“…Although the possibilities of considering PPIs as therapeutic options in COVID-19 have been proposed and discussed in some of the recent publications [45,51,52], the clinical evidence for the same is a mix bag. We have hypothesized their potential roles based on specific cellular mechanisms and summarized all the relevant findings and information till date to get a well-balanced and holistic view on the topic.…”

Section: Discussionmentioning

confidence: 99%

The Potential Therapeutic Role of Proton Pump Inhibitors in COVID-19: Hypotheses Based on Existing Evidences

2020

View full text Add to dashboard Cite

Although the major therapeutic uses of the proton pump inhibitors are in gastric-acid related diseases, evidences are suggestive of a pleiotropic nature of the compounds. We comment on the probable pathways and cellular machineries via which proton pump inhibitors could show beneficial therapeutic effects against SARS-CoV-2 based on the existing evidences. Proton pump inhibitors have shown antiviral potencies in various in vivo and in vitro studies. Some of the major possible ways through which they can act against SARS-CoV-2 are by exerting anti-inflammatory and anti-fibrotic effects, via vacuolar ATPase pumps leading to raised endolysosomal pH and by targeting endosomal complexes. The current pandemic has put forward a challenge to find treatment options. Although the potential roles of proton pump inhibitors against SARS-CoV-2 have been discussed in recent publications, the clinical evidences for their real-world effectiveness do not point towards a beneficial effect clearly yet. We suggest that although proton pump inhibitors should strongly be considered as potential therapeutic options for COVID-19, larger studies in the form of randomized controlled trials would be required to arrive at a definite conclusion.

show abstract

“…However, current use of PPIs conferred a 79% higher risk of severe clinical outcomes following SARS-CoV-2 infection. In contrast, Taştemur and Ataseven 138 hypothesised that PPI may be used for treatment and prophylaxis of COVID-19, owing to their anti-inflammatory, antioxidant, immunomodulatory and antifibrotic properties.…”

Section: Gi Side Effects Of Medications Used For Covid-19mentioning

confidence: 99%

Gastrointestinal manifestations in COVID-19

Kariyawasam

Jayarajah

Riza

et al. 2021

Transactions of the Royal Society of Tropical Medicine and Hygiene

113

105

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19), a respiratory viral infection, has affected more than 78 million individuals worldwide as of the end of December 2020. Previous studies reported that severe acute respiratory syndrome coronavirus 1 and Middle East respiratory syndrome–related coronavirus infections may affect the gastrointestinal (GI) system. In this review we outline the important GI manifestations of COVID-19 and discuss the possible underlying pathophysiological mechanisms and their diagnosis and management. GI manifestations are reported in 11.4–61.1% of individuals with COVID-19, with variable onset and severity. The majority of COVID-19-associated GI symptoms are mild and self-limiting and include anorexia, diarrhoea, nausea, vomiting and abdominal pain/discomfort. A minority of patients present with an acute abdomen with aetiologies such as acute pancreatitis, acute appendicitis, intestinal obstruction, bowel ischaemia, haemoperitoneum or abdominal compartment syndrome. Severe acute respiratory syndrome coronavirus 2 RNA has been found in biopsies from all parts of the alimentary canal. Involvement of the GI tract may be due to direct viral injury and/or an inflammatory immune response and may lead to malabsorption, an imbalance in intestinal secretions and gut mucosal integrity and activation of the enteric nervous system. Supportive and symptomatic care is the mainstay of therapy. However, a minority may require surgical or endoscopic treatment for acute abdomen and GI bleeding.

show abstract

Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis?

Cited by 23 publications

References 38 publications

In-Hospital Mortality and Prediction in an Urban U.S. Population With COVID-19

In-Hospital Mortality and Prediction in an Urban U.S. Population With COVID-19

The Potential Therapeutic Role of Proton Pump Inhibitors in COVID-19: Hypotheses Based on Existing Evidences

Gastrointestinal manifestations in COVID-19

Contact Info

Product

Resources

About